5th THERANOSTICS World Congress 2019 March 1 - 3, 2019 The Shilla Jeju Hotel, Jeju, Korea

SPEAKERS

  • cv
    Keynote 1 Sunghoon Kim Seoul National University
    Korea     Uncovering Novel Biomarkers for Next Generation Theranostics
  • cv
    Keynote 2 Michael Hofman Peter MacCallum Cancer Centre
    Australia     Practical Applications and Future Prospects of Radiotheranostics
  • cv
    Keynote 3 Hans-Jürgen Wester Technical University of Munich
    Germany     Radiohybrids: A Groundbreaking New Theranostics Tracer Concept
  • cv
    Keynote 4 Anthony Chang BAMF Health
    USA     Intelligence-based vs Evidence-based: How AI will Shape the Future of Theranostics to Achieve True Personalized Medicine
  • cv
    Keynote 5 Richard Baum Central Clinic Bad Berka
    Germany     Personalized Cancer Therapy: From Innovation to Implementation using Theranostics and Precision Oncology
  • cv
    Keynote 6 Dong Soo Lee Seoul National University
    Korea     Brain Theranostics
  • cv
    Min-Koo Han KAST
    Korea
  • cv
    Myung Chul Lee KAST
    Korea
  • cv
    Horacio Amaral PositronMed
    Chile
  • cv
    Vasko Kramer PositronPharma
    Chile
  • cv
    Kambiz Rahbar University Hospital Münster (UKM)
    Germany     Clinical Experiences with PSMA-1007: Current Status
  • cv
    Markus Essler University Hospital Bonn
    Germany     Clinical Experieces of Lu-177 PSMA Combined or for Other Cancers
  • cv
    Wolfgang Weber Technical University of Munich
    Germany     Future Perspectives of Theranostics in Germany
  • cv
    Richard Wahl Washington University
    USA     Future Perspectives of Theranostics in USA
  • cv
    Cheol Kwak Seoul National University
    Korea     Unmet Clinical Needs in Advanced Prostate Cancer
  • cv
    Yang-sook Chun Seoul National University
    Korea     New Therapeutic Target
  • cv
    Yun-Sang Lee Seoul National University
    Korea     Simplest Glu-Urea-Lys (EUK) for PSMA
  • cv
    Dae Yoon Chi Sogang University
    Korea     Theranostic Agents for Targeting PSMA: Development of F-18 and Alpha Emitters
  • cv
    Keon Wook Kang Seoul National University
    Korea     Theranostics in Korea
  • cv
    Seigo Kinuya Kanazawa University
    Japan     Theranostics in Japan
  • cv
    Feng Wang Nanjing Medical University
    China     Theranostics in China
  • cv
    Frank Rösch Institute of Nuclear Chemistry University Mainz
    Germany     Instant Kit-type Labelling Chemistry for 68Ga, 44Sc, 177Lu.
  • cv
    Henry VanBrocklin The University of California, San Francisco (UCSF)
    USA     Image Guided Therapy: Development of Oncologic and Non-oncologic Agents
  • cv
    Yuji Kuge Hokkaido University
    Japan     Potential Use of Hypoxia and Thymidine Phosphorylase Imaging Probes for Theranostics
  • cv
    Klaus Kopka German Cancer Research Center
    Germany     The Heidelberg Series of Glu-ureido based PSMA Tracers: Adaption of Chemical Structure to Clinical Indication
  • cv
    Jae Min Jeong Seoul National University
    Korea     Imaging of the Third Gasotransmitter
  • cv
    Cathy Cutler Brookhaven National Laboratory
    USA     Alpha-emitters
  • cv
    Michael K. Schultz University of Iowa Carver College of Medicine
    USA     Pb-203/Pb212 Peptide Receptor Targeted Theranostics for Cancer
  • cv
    Michael Zalutsky Duke University School of Medicine
    USA     Nanobodies: A Promising Platform for Theranostics Development
  • cv
    Mike Sathekge University of Pretoria
    South Africa     Implementation of Novel Theranostics in Africa
  • cv
    Patricia Bernal Trujillo Fundacion Santa Fe de Bogota University Hospital
    Colombia     Struggles of Theranostics in Latin America
  • cv
    Fani Bozkurt Hacettepe University
    Turkey     Theranostics Efforts between Europe and Asia
  • cv
    Partha Choudhury Rajiv Gandhi Cancer Institute & Research Centre
    India     Optimization of Novel Radionuclide Therapies in India
  • cv
    Akram Al-Ibraheem King Hussein Cancer Center
    Jordan     Theranostics in Arab
  • cv
    Mark Konijnenberg Erasmus Medical Center
    The Netherlands     Prospective Dosimetry Options for Alpha-emitter Targeted Therapy
  • cv
    Jae Sung Lee Seoul National University
    Korea     New Approaches to Fast Voxel-based Dosimetry
  • cv
    Greta Seng Peng Mok University of Macau
    Macau     3D Voxel Dosimetry
  • cv
    Makoto Hosono Kindai University
    Japan     ICRP Perspectives for Individualized Radionuclide Therapy
  • cv
    Lingeswaran Kasilingam Beacon Hospital
    Malaysia
  • cv
    Hendra Budiawan Hasan Sadikin Hospital, Bandung
    Indonesia
  • cv
    Pham Cam Phuong Bach Mai Hospital
    Vietnam
  • cv
    Shamim Momtaz Ferdousi Begum National Institute of Nuclear Medicine & Allied Sciences
    Bangladesh
  • cv
    David Ng Singapore General Hospital
    Singapore
  • cv
    Hong Zhang Shanxi Medical University
    China
  • cv
    Humayun Bashir Shaukat Kjanum Memorial Cancer Hospital & Research Centre
    Pakistan
  • cv
    Anna Wu University of California Los Angeles
    USA     Antibody Theranostics
  • cv
    Young Kee Shin Seoul National University
    Korea     In Vitro to in Vivo Companion Diagnostics
  • cv
    Jung-Joon Min Chonnam National University
    Korea     Bacteria-based Radio-theranostics
  • cv
    Andrei Iagaru Stanford University
    USA     Gastrin-Releasing Peptide Receptors for Theranostics in Prostate Cancer
  • cv
    Michael Kreissl University Hospital Magdeburg
    Germany     Theranostics in Combination with Local Therapies
  • cv
    Matthias Eiber Technical University of Munich
    Germany     PSMA Targeting Alpha Therapies
  • cv
    Il Minn Johns Hopkins University
    USA     Immune Cell-based Theranostics
  • cv
    Steve Cho University of Wisconsin School of Medicine and Public Health
    USA     Porposed Criteria Positions PSMA for the Future
  • cv
    Josh Mailman NorCal CarciNet Community
    USA     USA Experiences
  • cv
    Song-hoon Ham
    Korea     Korean Experiences
  • cv
    Yoshiyuki Majima NPO PanCAN
    Japan     Japanese Experiences
  • cv
    Beat Loeffler CLINAM - European Foundation for Clinical Nanomedicine
    Switzerland     Nanomedicine: 11 Years of European Efforts
  • cv
    Dong Soo Lee Seoul National University
    Korea     Introduction to Radionanomedicine
  • cv
    Weibo Cai University of Wisconsin–Madison
    USA     Radiolabeled Nanomaterials: Ready for Clinical Translation
  • cv
    Seung-Hoon Lee Seoul National University
    Korea     Ceria-based Nanoparticle Therapy for ROS-mediated Injury

KEY DATES

NEWS & NOTICE

News & Notices

Download Center

PAST CONGRESS

Organized by
Supported by
Gold
Silver